Newsletter Signup - Under Article / In Page"*" indicates required fields Cancer has long been one of the most persistent and deadly diseases, and with its ability to evolve, resist treatment, and spread relentlessly, it has left scientists grappling for solutions. Yet, amid the uncertainty, the landscape of cancer treatments is shifting. Once limited to chemotherapy and radiation, treatment options have expanded since and continue to do so. Largely thanks to this, cancer death rates have fallen by 33% in the U.S. since 1991. As we observe World Cancer Day today, let us look at some of the trends in oncology expected to improve cancer care in 2025.While the number of clinical trials for cancer has been growing, they have been moving towards “innovative designs and patient-centric approaches,” according to Stephan Schann, chief scientific officer of French biotech Domain Therapeutics.“The industry has witnessed increased investment in platforms that address previously ‘undruggable’ targets and I expect this theme to continue into 2025

Newsletter Signup - Under Article / In Page"*" indicates required fields The past year has been one of ups and downs for the biotech and healthcare sectors in the U.K. A report by the UK BioIndustry Association (BIA) revealed how investments played a part in research and development (RD) in the country. Equity financing was at quite a high last year. Around £3.5 billion ($4.36 million) was raised by the industry – a 94% increase from 2023. This highlights “renewed confidence and the resilience of the U.K. biotech industry,” according to Steve Bates, chief executive officer (CEO) of BIA.“This year’s figures demonstrate that biotech is a vibrant growth sector of the U.K. economy with an exceptional ability to attract global investment

Here's why Merck & Co., Inc. (MRK) is among the Highest Yielding Dividend Stocks in the Dow.